CCR5 blockade for neuroinflammatory diseases-beyond control of HIV

Nature Reviews Neurology

Volumn 12, Issue 2, 2016, Pages 95-105

  Martin Blondel, Guillaume ^a,b   Brassat, David ^a,b   Bauer, Jan ^c   Lassmann, Hans ^c   Liblau, Roland S ^b  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b CHU PURPAN   (France)

^c Medical University of Vienna   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CCR7; IMMUNOMODULATING AGENT; MARAVIROC; NEUROPROTECTIVE AGENT;

ANTIVIRAL ACTIVITY; BRAIN MALARIA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CROSS PRESENTATION; DRUG EFFICACY; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; ENCEPHALITIS; HEMISPHERECTOMY; HETEROZYGOSITY; HIV ASSOCIATED DEMENTIA; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE SYSTEM; IMMUNOMODULATION; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RASMUSSEN ENCEPHALITIS; REVIEW; VIRUS REPLICATION; ANIMAL; CENTRAL NERVOUS SYSTEM DISEASES; DRUG EFFECTS; HIV INFECTIONS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CCR5 RECEPTOR ANTAGONISTS; CENTRAL NERVOUS SYSTEM DISEASES; HIV INFECTIONS; HUMANS; NEUROIMMUNOMODULATION; NEUROPROTECTIVE AGENTS; RECEPTORS, CCR5;

EID: 84957851765     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2015.248     Document Type: Review

References (69)

1. Jack, C. R., et al. An operational approach to NIA-AA crtiteria for preclinical Alzheimers disease. Ann. Neurol. 71, 765-775 (2012).
2. Sperling, R. A., et al. Toward defining the preclinical stages of Alzheimers disease: recommendations from the National Institute on Aging-Alzheimers Assocation workgroups on diagnostic guidelines for Alzheimers disease. Alzheimers Dement. 7, 280-292 (2011).
3. Albert, M. S., et al. The diagnosis of mild cognitive impairment due to Alzheimers disease: recommendations from the National Institute on Aging and Alzheimers Association Workgroup. Alzheimers Dement. 7, 270-279 (2011).
4. McKhann, G. M., et al. The diagnosis of dementia due to Alzheimers disease: recommendations from the National Institute on Aging and the Alzheimers Assocation Workgroup. Alzheimers Dement. 7, 263-269 (2011).
5. Jack, C. R., et al. Introduction to the recommendations from the National Institute on Aging-Alzheimers Association workgroups on diagnostic guidelines for Alzheimers disease. Alzheimers Dement. 7, 257-262 (2011).
6. Senjem, M. L., et al. Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease. NeuroImage 26, 600-608 (2005).
7. Duyckaerts, C., et al. PART is part of Alzheimer disease. Acta Neuropathol. 129, 749-756 (2012).
8. Knopman, D. S., et al. Short-Term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 78, 1576-1582 (2012).
9. Mormino, E. C., et al. Synergistic effect of β-Amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol. 71, 1379-1385 (2014).
10. Ivanoiu, A., et al. Classification of non-Demented patients attending a memory clinic using the new diagnostic criteria for Alzheimers disease with disease-related biomarkers. J. Alzheimers Dis. 43, 835-847 (2015).
11. Wirth, M., et al. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol. 70, 1512-1519 (2013).
12. Vos, S. J., et al. Preclinical Alzheimers disease and its outcome: a longitudinal cohort study. Lancet Neurol. 12, 957-965 (2013).
13. Roe, C. M., et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 80, 1784-1791 (2013).
14. van Harten, A. C., et al. Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology 81, 1409-1416 (2013).
15. Toledo, J. B., et al. Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathol. Commun. 2, 26 (2014).
16. Morris, J. C., et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann. Neurol. 67, 122-131 (2010).
17. Vemuri, P., et al. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann. Neurol. 67, 308-316 (2010).
18. Lim, S. M., et al. The 18F-FDG PET cingulate island sign and comparison to 123I-β-CIT SPECT for diagnosis of dementia with Lewy bodies. J. Nucl. Med. 50, 1638-1645 (2009).
19. Knopman, D. S., et al. Brain injury biomarkers are not dependent on β-Amyloid in normal elderly. Ann. Neurol. 73, 472-480 (2013).
20. Jack, C. R., et al. Age-specific population frequencies of cerebral β-Amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. Lancet Neurol. 13, 997-1005 (2014).
21. Jack, C. R., et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 81, 1732-1740 (2013).
22. Villain, N., et al. Regional dynamics of amyloid-â deposition in healthy elderly, mild cognitive impairment and Alzheimers disease: a voxelwise PiB-PET longitudinal study. Brain 135, 2126-2139 (2012).
23. Villemagne, V. L., et al. Amyloid â deposition, neurodegeneration, and cognitive decline in sporadic Alzheimers disease: a prospective cohort study. Lancet Neurol. 12, 357-367 (2013).
24. Jack, C. R., et al. Brain β-Amyloid load approaches a plateau. Neurology 80, 890-896 (2013).
25. Jellinger, K. A., et al. PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol. 129, 757-762 (2015).
26. Duyckaerts, C., & Hauw, J. J. Prevalence, incidence and duration of Braaks stages in the general population: can we know? Neurobiol. Aging 18, 362-369; discussion 89-92 (1997).
27. Duyckaerts, C., Uchihara, T., Seilhean, D., He, Y., & Hauw, J. J. Dissociation of Alzheimer type pathology in a disconnected piece of cortex. Acta Neuropathol. 93, 501-507 (1997).
28. Delacourte, A., et al. Tau aggregation in the hippocampal formation: an ageing or a pathological process? Exp. Gerontol. 37, 1291-1296 (2002).
29. Price, J. L., & Morris, J. C. Tangles and plaques in nondemented aging and preclinical Alzheimers disease. Ann. Neurol. 45, 358-368 (1999).
30. Hyman, B. T., et al. National Institute on Aging- Alzheimers Association guidelines for the neuropathologic assessment of Alzheimers disease. Alzheimers Dement. 8, 1-13 (2012).
31. Montine, T. J., et al. National Institute on Aging- Alzheimers Association guidelines for the neuropathologic assessment of Alzheimers disease: a practical approach. Acta Neuropathol. 123, 1-11 (2012).
32. Murray, M. E., et al. The relationship of primary age-related tauopathy (PART) to SNAP: controversy or parallel? Presented at the Alzheimers Association International Conference (2015).
33. Tapiola, T., et al. Cerebrospinal fluid β-Amyloid 42 and tau proteins as biomarkers of Alzheimer-Type pathologic changes in the brain. Arch. Neurol. 66, 382-389 (2009).
34. Morra, J. H., et al. Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimers disease, mild cognitive impairment, and elderly controls. Hum. Brain Mapp. 30, 2766-2788 (2009).
35. Jack, C. R., et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 58, 750-757 (2002).
36. Nelson, P. T., et al. Hippocampal sclerosis of aging, a prevalent and high-morbidity brain disease. Acta Neuropathol. 126, 161-177 (2013).
37. Probst, A., Taylor, K. I., & Tolnay, M. Hippocampal sclerosis dementia: a reappraisal. Acta Neuropathol. 114, 335-345 (2007).
38. Whitwell, J. L., et al. Does TDP-43 type confer a distinct pattern of atrophy in frontotemporal lobar degeneration? Neurology 75, 2212-2220 (2010).
39. Di Paola, M., et al. Hippocampal atrophy is the critical brain change in patients with hypoxic amnesia. Hippocampus 18, 719-728 (2008).
40. Josephs, K. A., et al. Fluorodeoxyglucose F18 positron emission tomography in progressive apraxia of speech and primary progressive aphasia variants. Arch. Neurol. 67, 596-605 (2010).
41. Villain, N., et al. Relationships between hippocampal atrophy, white matter disruption, and gray matter hypometabolism in Alzheimers disease. J. Neurosci. 28, 6174-6181 (2008).
42. Villain, N., et al. Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimers disease. Brain 133, 3301-3314 (2010).
43. Buckner, R. L., et al. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimers disease. J. Neurosci. 29, 1860-1873 (2009).
44. Sperling, R. A., et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 63, 178-188 (2009).
45. Rosenzweig, E. S., & Barnes, C. A. Impact of aging on hippocampal function: plasticity, network dynamics, and cognition. Prog. Neurobiol. 69, 143-179 (2003).
46. Yeoman, M., Scutt, G., & Faragher, R. Insights into CNS ageing from animal models of senescence. Nat. Rev. Neurosci. 13, 435-445 (2012).
47. Tsitsopoulos, P. P., & Marklund, N. Amyloid-β peptides and tau protein as biomarkers in cerebrospinal and interstitial fluid following traumatic brain injury: a review of experimental and clinical studies. Front. Neurol. 4, 79 (2013).
48. Hardy, J. The amyloid hypothesis for Alzheimers disease: a critical reappraisal. J. Neurochem. 110, 1129-1134 (2009).
49. Chetelat, G. Alzheimer disease: a β-independent processes-rethinking preclinical AD. Nat. Rev. Neurol. 9, 123-124 (2013).
50. Herrup, K. Reimagining Alzheimers disease - an age-based hypothesis. J. Neurosci. 30, 16755-16762 (2010).
51. Resnick, S. M. Preclinical biomarkers in Alzheimer disease: a sum greater than the parts. JAMA Neurol. 71, 1357-1358 (2014).
52. Kawas, C. H., et al. Multiple pathologies are common and related to dementia in the oldest-old: the 90+ Study. Neurology 85, 535-542 (2015).
53. Jack, C. R., et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimers disease: implications for sequence of pathological events in Alzheimers disease. Brain 132, 1355-1365 (2009).
54. Mormino, E. C., et al. Episodic memory loss is related to hippocampal-mediated β-Amyloid deposition in elderly subjects. Brain 132, 1310-1323 (2009).
55. Perrin, R. J., Fagan, A. M., & Holtzman, D. M. Multimodal techniques for diagnosis and prognosis of Alzheimers disease. Nature 461, 916-922 (2009).
56. Goate, A., et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimers disease. Nature 349, 704-706 (1991).
57. Jonsson, T., et al. A mutation in APP protects against Alzheimers disease and age-related cognitive decline. Nature 488, 96-99 (2012).
58. Hutton, M., et al. Association of missense and 5?-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702-705 (1998).
59. Jack, C. R., et al. Tracking pathophysiological processes in Alzheimers disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207-216 (2013).
60. Jack, C. R., et al. Hypothetical model of dynamic biomarkers of the Alzheimers pathological cascade. Lancet Neurol. 9, 119-128 (2010).
61. Jack, C. R., et al. Evidence for ordering of Alzheimer disease biomarkers. Arch. Neurol. 68, 1526-1535 (2011).
62. Jack, C. R. Jr, Holtzman, D. M. Biomarker modeling of Alzheimers disease. Neuron 80, 1347-1358 (2013).
63. Musiek, E. S., & Holtzman, D. M. Origins of Alzheimers disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement. Curr. Opin. Neurol. 25, 715-720 (2012).
64. Delacourte, A., et al. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimers disease. Neurology 59, 398-407 (2002).
65. Jack, C. R., et al. Rates of β-Amyloid accumulation are independent of hippocampal neurodegeneration. Neurology 82, 1605-1612 (2014).
66. Knopman, D. S., et al. Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-Amyloidosis. JAMA Neurol. 70, 1030-1038 (2013).
67. Maruyama, M., et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79, 1094-1108 (2013).
68. Chien, D. T., et al. Early clinical PET imaging results with the novel PHF-Tau radioligand [F-18]-T807. J. Alzheimers Dis. 34, 457-468 (2013).
69. Villemagne, V. L., et al. In vivo evaluation of a novel tau imaging tracer for Alzheimers disease. Eur. J. Nucl. Med. Mol. Imaging 41, 816-826 (2014).